Every treatment we track, side by side. Same information, same order, every time.
fam-trastuzumab deruxtecan-nxki
HER2-directed antibody-drug conjugate for selected breast and other HER2-expressing cancers
palbociclib
CDK4/6 inhibitor for selected HR+/HER2- metastatic breast cancer settings
ado-trastuzumab emtansine
HER2-directed ADC for selected HER2+ breast cancer settings
ribociclib
CDK4/6 inhibitor for selected HR+/HER2- breast cancer settings
olaparib
PARP inhibitor for selected BRCA-mutated breast and other cancers
pertuzumab
HER2-targeted therapy for selected HER2+ breast cancer settings
sacituzumab govitecan-hziy
TROP-2 antibody-drug conjugate for selected breast cancer settings
abemaciclib